Nicotinamide and nicotinic acid are the two well known niacins, i.e., vitamin precursors of NAD+ that are useful for stroke and dyslipidemias including hypercholesterolemia, respectively. Use of nicotinic acid is greatly limited by side-effects termed flushing. In addition, there is growing evidence that nicotinamide promotes aging in experimental systems, causing concern that nicotinamide may have negative side-effects.
Nicotinamide riboside is an additional NAD+ precursor that is soluble and transportable and may be useful for conditions requiring elevation of NAD+ levels or altering the levels of NAD+ precursors. Dartmouth scientists have developed a sensitive biological assay that uniquely detects nicotinamide riboside and not NAD+, nicotinamide mononucleotide, nicotinamide, nicotinic acid, tryptophan or any other NAD+ precursor.
These findings are claimed in the published United States Patent Application Nos. 11/542,832, 11/912,400, and 12/411,586 as well as several pending and published foreign applications. We are seeking an industrial partner to further refine and market this technology. (Ref: J263)
Last Updated: 7/24/12